INMB vs ROL · rev $50.0K vs P/E 41, rev $1.99B
INmune Bio Inc (INMB) versus Rollins Inc (ROL) — a side-by-side from cached financials, not a winner call.
INmune Bio Inc (INMB) is a biotechnology company listed on US.
Rollins Inc (ROL) is a personal services company listed on NYSE.
Latest reported INMB revenue for 2025-09-30 was $50.0K. Net income was -$6.5M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. INMB currently screens at market cap $33.5M.
Latest reported ROL revenue for 2026-06-30 was $1.99B. Net income was $251.7M. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
INMB currently screens at market cap $33.5M. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
Not investment advice. Open the INMB and ROL stock pages for the full models.
Not investment advice.